Pricing Log in Create free account
Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.03
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 2 — — — — — 1 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 6.29%

Capital & Financial Ratios $m

Market Cap 92.41
Revenue 243.06
Net Income 38.59
Free Cash Flow 33.40
Net Debt (63.98)
Current Ratio 1.60 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 2.75
Fwd P/E 2.14
P/S ratio 0.44
P/B ratio 1.29
Past 5Y EPS Growth —
This Y EPS Growth 12.12%
Next Y EPS Growth (17.24%) (below 0%: weak)
Next Y revenue growth (50.01%) (below 0%: weak)
Next 5Y EPS Growth (6.35%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 1.7×; over the ten years it ranged from −4.7× in 2017 to 1,035× in 2022.
P/S against its own 10 years 7.46%
10-year low 10-year high
P/B against its own 10 years 38.04%
10-year low 10-year high
EV/Sales against its own 10 years 3.11%
10-year low 10-year high
EV/FCF against its own 10 years 59.72%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 40 52 64 64
Receivables 3 12 51 47
Inventory — — — —
Other — — — —
46 68 136 117
2023 2024 2025 Q'26
Payables 2 7 21 17
ST’ Debt — — — —
Other 4 4 1 3
14 91 87 73

Compound Annual Growth %

10y 5y 3y
Sales 38.25% 125.76% 1,204.00%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 6.63% (6.58%) (7.41%)

Revenue $m

Mar Jun Sep Dec Year
’26 39 27 — — —
’25 21 40 72 104 237
’24 2 6 5 15 29
’23 1 1 2 3 7
’22 0 — — 0 0
’21 1 0 0 0 1
’20 3 1 0 0 4
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 3 — — —
’25 (10) (16) 3 31 8
’24 (21) (12) (4) (7) (45)
’23 (24) (17) (15) (14) (70)
’22 (25) (26) (15) (29) (95)
’21 (17) (13) (14) (16) (60)
’20 (3) (1) (9) (11) (24)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 3 — — —
’25 (10) (16) 2 31 8
’24 (21) (12) (4) (7) (45)
’23 (26) (18) (15) (13) (72)
’22 (26) (28) (17) (33) (104)
’21 (17) (15) (16) (17) (65)
’20 (3) (1) (10) (12) (25)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.02 (0.06) — — —
’25 (0.07) (0.07) (0.04) 0.24 0.07
’24 (0.14) (0.09) (0.06) (0.05) (0.33)
’23 (0.19) (0.16) (0.11) (0.12) (0.57)
’22 (0.20) (0.23) (0.23) (0.18) (0.84)
’21 (0.14) (0.13) (0.14) (0.17) (0.58)
’20 (0.02) (0.12) (0.08) (0.13) (0.36)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 12.54 4.73 1.83 0.25 0.30 4.86 0.73 0.53 0.52 0.26

Analyst estimates 2026–2028

Powerpack
High 24.97 16.50 9.46 5.00 17.49 24.90 6.80 1.59 1.54 0.98
People
People Employees 21 16 34 14 28 15 164 109 105 65
Revenue/emp, $m 0.00 0.00 0.12 0.70 0.14 0.06 0.00 0.07 0.27 3.65
Income, $m
Income, $m Revenue 9 6 4 10 4 1 0 7 29 237
Gross margin, % 98.92 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (25) (10) (18) (18) (32) (70) (108) (82) (67) 17
EBT margin, % (273.12) (164.10) (430.34) (184.09) (790.46) (7,888.23) (100,645.79) (1,114.03) (232.36) 7.08
Net income (25) (10) (18) (19) (32) (70) (108) (82) (67) 16
Depreciation 0 1 3 4 3 4 6 8 8 8
Per share, $
Per share, $ Revenue 2.65 42.93 0.66 0.46 0.05 0.01 0.00 0.05 0.14 1.03
Earnings (7.26) (8.36) (2.90) (0.86) (0.36) (0.58) (0.84) (0.57) (0.33) 0.07
Cash flow (4.01) (73.82) (2.30) (0.61) (0.27) (0.49) (0.74) (0.49) (0.22) 0.03
Capex 0.00 (0.35) (0.11) (0.04) (0.01) (0.04) (0.08) (0.01) 0.00 0.00
Free cash flow (4.01) (74.17) (2.42) (0.65) (0.28) (0.54) (0.82) (0.50) (0.22) 0.03
Book value 13.15 (284.72) 1.78 0.60 1.40 1.54 0.87 0.40 0.29 0.38
Shares, m 4 0 6 22 88 121 128 145 202 230
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.83
P/S 4.29 2.68 2.86 0.77 124.61 853.72 315.02 11.97 4.65 0.34
P/B 1.67 0.00 1.06 0.58 4.09 4.06 1.09 1.53 2.26 0.92
EV/Sales (0.21) 7.28 0.56 (0.49) 93.54 668.39 66.88 6.75 2.89 0.08
EV/FCF 0.05 (6.12) (0.15) 0.34 (15.16) (9.17) (0.24) (0.69) (1.83) 2.37
Cash, $m
Cash, $m Operating cash flow (14) (10) (15) (13) (24) (60) (95) (70) (45) 8
Capex 0 0 (1) (1) (1) (5) (10) (2) (1) 0
Free cash flow (14) (10) (15) (14) (25) (65) (104) (72) (45) 8
Balance, $m
Balance, $m Working capital 63 (1) 7 8 117 158 82 32 (23) 49
Total debt 0 39 2 15 17 23 25 — — —
Net debt (69) 36 (10) (14) (127) (166) (96) (40) (52) (64)
Shareholders’ equity 46 (39) 11 13 123 188 111 58 59 88
Returns, %
Returns, % ROA (34.94) (55.85) (92.31) (51.61) (33.98) (37.71) (57.47) (67.13) (51.85) 9.26
ROIC 0.00 0.00 (811.31) 0.00 0.00 (216.07) (481.30) (287.93) (575.30) 47.09
ROE (54.98) 124.46 133.50 (154.15) (47.26) (45.33) (72.29) (97.94) (114.71) 22.26
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

VAXART, INC. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OKUR OnKure Therapeutics, Inc. $93.2M — (loss-making) — — n/m +22.05% (above 0%: growing) 0.00% 0.00% Compare
ATRA Atara Biotherapeutics, Inc. $92.6M — (loss-making) — (loss-making) −96.42% (below 0%: shrinking) n/m +52.10% (above 0%: growing) 69.68% (749.21%) Compare
VXRT VAXART, INC. $92.4M 2.8× 2.1× −31.58% (below 0%: shrinking) n/m +117.38% (above 0%: growing) 100.00% (48.45%)
EQ Equillium, Inc. $91.3M — (loss-making) — (loss-making) −52.32% (below 0%: shrinking) n/m −38.67% (below 0%: shrinking) 100.00% 0.00% Compare
CLLS Cellectis S.A. $90.4M — (loss-making) — −62.05% (below 0%: shrinking) n/m −36.95% (below 0%: shrinking) 100.00% (340.69%) Compare
RLYB Rallybio Corporation $90.2M 2.1× — (loss-making) 0.00% n/m +648.02% (above 0%: growing) 100.00% 0.00% Compare
NMRA Neumora Therapeutics, Inc. $90.2M — (loss-making) — — n/m +24.45% (above 0%: growing) 0.00% 0.00% Compare
MIST Milestone Pharmaceuticals Inc. $88.7M — (loss-making) — (loss-making) −62.73% (below 0%: shrinking) n/m −80.81% (below 0%: shrinking) 94.28% (4,584.97%) Compare
ICCC ImmuCell Corporation $88.6M 114× — (loss-making) +11.50% (above 0%: growing) +233.33% (above 0%: growing) +54.86% (above 0%: growing) 33.92% 26.93% Compare
Median of peers $90.3M — — −57.18% — +23.25% 81.98% 0.00%

All 614 Biotechnology stocks →

VAXART, INC. (VXRT) key facts

  • Strength: VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024.
  • VAXART, INC. (VXRT) is a Biotechnology company in the Healthcare sector.
  • As of October 9, 2026, VXRT traded at $0.43, a market capitalization of $92.4 million.
  • Return on equity was 22.3% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −1.06 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

VAXART, INC. (VXRT) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/VXRT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com